These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16856889)

  • 21. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
    Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
    Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A
    Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577
    [No Abstract]   [Full Text] [Related]  

  • 23. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
    Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
    Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibitors in non-Hodgkin's lymphoma.
    Zelenetz A
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S34-6. PubMed ID: 16280110
    [No Abstract]   [Full Text] [Related]  

  • 28. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
    Fisher RI
    J Clin Oncol; 2005 Feb; 23(4):657-8. PubMed ID: 15613690
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
    O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
    Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
    Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
    Leyva S; Marino-Vázquez LA; Reyes-Loaeza JA; Vega O; Uribe-Uribe N; Alberú J; Morales-Buenrostro LE
    Clin Transpl; 2009; ():369-76. PubMed ID: 20524300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
    Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U
    Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
    Engel RH; Brown JA; Von Roenn JH; O'Regan RM; Bergan R; Badve S; Rademaker A; Gradishar WJ
    Cancer Invest; 2007 Dec; 25(8):733-7. PubMed ID: 17952740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.